RU2016117775A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2016117775A3 RU2016117775A3 RU2016117775A RU2016117775A RU2016117775A3 RU 2016117775 A3 RU2016117775 A3 RU 2016117775A3 RU 2016117775 A RU2016117775 A RU 2016117775A RU 2016117775 A RU2016117775 A RU 2016117775A RU 2016117775 A3 RU2016117775 A3 RU 2016117775A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1716—Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361888269P | 2013-10-08 | 2013-10-08 | |
| US61/888,269 | 2013-10-08 | ||
| US201461992807P | 2014-05-13 | 2014-05-13 | |
| US61/992,807 | 2014-05-13 | ||
| US201462004828P | 2014-05-29 | 2014-05-29 | |
| US201462004836P | 2014-05-29 | 2014-05-29 | |
| US62/004,828 | 2014-05-29 | ||
| US62/004,836 | 2014-05-29 | ||
| PCT/US2014/059699 WO2015054390A1 (en) | 2013-10-08 | 2014-10-08 | Methods for treating fibrotic cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020111934A Division RU2020111934A (ru) | 2013-10-08 | 2014-10-08 | Способы лечения фиброзного рака |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016117775A RU2016117775A (ru) | 2017-11-15 |
| RU2016117775A3 true RU2016117775A3 (enExample) | 2018-07-27 |
| RU2718056C2 RU2718056C2 (ru) | 2020-03-30 |
Family
ID=52813618
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020111934A RU2020111934A (ru) | 2013-10-08 | 2014-10-08 | Способы лечения фиброзного рака |
| RU2016117775A RU2718056C2 (ru) | 2013-10-08 | 2014-10-08 | Способы лечения фиброзного рака |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020111934A RU2020111934A (ru) | 2013-10-08 | 2014-10-08 | Способы лечения фиброзного рака |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11020451B2 (enExample) |
| EP (2) | EP3054959B1 (enExample) |
| JP (2) | JP6636914B2 (enExample) |
| CN (2) | CN114053395A (enExample) |
| AU (2) | AU2014331954B2 (enExample) |
| CA (1) | CA2926418A1 (enExample) |
| ES (1) | ES2784234T3 (enExample) |
| PL (1) | PL3054959T3 (enExample) |
| RU (2) | RU2020111934A (enExample) |
| WO (1) | WO2015054390A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2020111934A (ru) | 2013-10-08 | 2020-04-29 | Промедиор, Инк. | Способы лечения фиброзного рака |
| US20180318303A1 (en) * | 2015-04-15 | 2018-11-08 | Promedior, Inc. | Methods for treating myeloproliferative disorders |
| KR102066402B1 (ko) * | 2017-12-22 | 2020-01-15 | 대화제약 주식회사 | 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물 |
| SG11202006782YA (en) * | 2018-01-31 | 2020-08-28 | Twi Pharmaceuticals Inc | Topical formulations comprising tofacitinib |
| CA3093749A1 (en) * | 2018-03-28 | 2019-10-03 | Blade Therapeutics, Inc. | Method of treating fibrotic disease |
| CN108715865B (zh) * | 2018-05-28 | 2021-09-21 | 福建师范大学 | 用于提高细胞转染效率的试剂组合物 |
| CA3128081A1 (en) | 2019-02-12 | 2020-08-20 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
| US20220202803A1 (en) * | 2019-04-25 | 2022-06-30 | Clear Creek Bio, Inc. | Combination therapies including inhibitors of dihydroorotate dehydrogenase |
| CN112107556A (zh) * | 2019-06-03 | 2020-12-22 | 北京大学 | 一种含砷纳米药物及其制备方法 |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| US20230089484A1 (en) * | 2020-01-28 | 2023-03-23 | Raziel Therapeutics Ltd. | Compositions for the treatment of angiolipoma |
| KR102725907B1 (ko) * | 2021-11-25 | 2024-11-04 | 성균관대학교산학협력단 | 파크리티닙을 이용한 항암제 내성 암 치료를 위한 병용 요법 |
| AU2024239074A1 (en) * | 2023-03-17 | 2025-10-02 | Mdx Management Llc | Compositions and methods for ameliorating adverse effects of therapies |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| WO1999004819A1 (en) | 1997-07-24 | 1999-02-04 | Inex Pharmaceuticals Corporation | Liposomal compositions for the delivery of nucleic acid catalysts |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US7763256B2 (en) | 2002-12-23 | 2010-07-27 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation |
| US8012472B2 (en) * | 2002-12-23 | 2011-09-06 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes |
| EP1711196A4 (en) | 2003-12-05 | 2011-09-14 | Bristol Myers Squibb Co | INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS |
| AU2006211960A1 (en) * | 2005-02-08 | 2006-08-17 | Board Of Regents, The University Of Texas System | Compositions and methods involving MDA-7 for the treatment of cancer |
| GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| ES2599319T3 (es) * | 2006-06-26 | 2017-02-01 | Macrogenics, Inc. | Anticuerpos específicos de Fc RIIB y métodos de uso de éstos |
| ES2409756T3 (es) * | 2006-12-04 | 2013-06-27 | Promedior, Inc. | Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos |
| PL2185581T3 (pl) * | 2007-07-06 | 2016-01-29 | Promedior Inc | Sposoby i kompozycje użyteczne do leczenia zapalenia błony śluzowej |
| US8497243B2 (en) * | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
| US9884899B2 (en) * | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
| CA2754961C (en) | 2009-03-11 | 2018-04-10 | Promedior, Inc. | Treatment and diagnostic methods for hypersensitive disorders |
| EP2405929B1 (en) * | 2009-03-11 | 2018-06-06 | Promedior Inc. | A sap polypeptide for use in the treatment of autoimmune disorders and graft vs host disease |
| JP2012522798A (ja) | 2009-04-01 | 2012-09-27 | プロメディオール， インコーポレイテッド | 血清アミロイドｐの肺および鼻への送達 |
| UA110323C2 (en) * | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
| EP2987803B1 (en) | 2009-06-17 | 2018-08-29 | Promedior Inc. | Sap variants and their use |
| ES2728446T3 (es) | 2011-12-21 | 2019-10-24 | Promedior Inc | Proteínas de fusión de P-anticuerpos de amiloide sérico |
| JP2015069119A (ja) | 2013-09-30 | 2015-04-13 | パナソニック液晶ディスプレイ株式会社 | 表示装置 |
| RU2020111934A (ru) | 2013-10-08 | 2020-04-29 | Промедиор, Инк. | Способы лечения фиброзного рака |
| US20180318303A1 (en) | 2015-04-15 | 2018-11-08 | Promedior, Inc. | Methods for treating myeloproliferative disorders |
-
2014
- 2014-10-08 RU RU2020111934A patent/RU2020111934A/ru unknown
- 2014-10-08 CN CN202111292205.8A patent/CN114053395A/zh active Pending
- 2014-10-08 EP EP14851638.8A patent/EP3054959B1/en active Active
- 2014-10-08 PL PL14851638T patent/PL3054959T3/pl unknown
- 2014-10-08 WO PCT/US2014/059699 patent/WO2015054390A1/en not_active Ceased
- 2014-10-08 CA CA2926418A patent/CA2926418A1/en active Pending
- 2014-10-08 JP JP2016521266A patent/JP6636914B2/ja active Active
- 2014-10-08 CN CN201480062728.5A patent/CN105792831A/zh active Pending
- 2014-10-08 AU AU2014331954A patent/AU2014331954B2/en not_active Ceased
- 2014-10-08 EP EP20150541.9A patent/EP3718558A1/en not_active Withdrawn
- 2014-10-08 RU RU2016117775A patent/RU2718056C2/ru active
- 2014-10-08 US US15/027,759 patent/US11020451B2/en active Active
- 2014-10-08 ES ES14851638T patent/ES2784234T3/es active Active
-
2019
- 2019-12-19 JP JP2019229263A patent/JP7140739B2/ja active Active
-
2020
- 2020-08-20 AU AU2020220139A patent/AU2020220139A1/en not_active Abandoned
-
2021
- 2021-04-27 US US17/241,654 patent/US20210322515A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014331954B2 (en) | 2020-05-21 |
| JP2020059752A (ja) | 2020-04-16 |
| JP6636914B2 (ja) | 2020-01-29 |
| AU2020220139A1 (en) | 2020-09-10 |
| CA2926418A1 (en) | 2015-04-16 |
| RU2016117775A (ru) | 2017-11-15 |
| EP3054959B1 (en) | 2020-01-08 |
| US20210322515A1 (en) | 2021-10-21 |
| CN114053395A (zh) | 2022-02-18 |
| JP2016539087A (ja) | 2016-12-15 |
| AU2014331954A1 (en) | 2016-04-21 |
| US11020451B2 (en) | 2021-06-01 |
| EP3054959A4 (en) | 2017-04-26 |
| US20160235812A1 (en) | 2016-08-18 |
| PL3054959T3 (pl) | 2020-07-13 |
| JP7140739B2 (ja) | 2022-09-21 |
| CN105792831A (zh) | 2016-07-20 |
| EP3054959A1 (en) | 2016-08-17 |
| RU2020111934A (ru) | 2020-04-29 |
| EP3718558A1 (en) | 2020-10-07 |
| RU2718056C2 (ru) | 2020-03-30 |
| WO2015054390A1 (en) | 2015-04-16 |
| ES2784234T3 (es) | 2020-09-23 |